AVG 001
Alternative Names: AVG-001Latest Information Update: 12 Oct 2023
At a glance
- Originator AlveoGene
- Class Gene therapies
- Mechanism of Action Alpha 1-antitrypsin stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency
Most Recent Events
- 14 Sep 2023 AlveoGene in-licenses lentiviral delivery platform technology from the UK Respiratory Gene Therapy Consortium
- 14 Sep 2023 Preclinical trials in Alpha 1-antitrypsin deficiency in United Kingdom (Inhalation)
- 14 Sep 2023 AlveoGene plans a clinical trial for Alpha 1-antitrypsin deficiency by 2026 (Inhalation)